$COGT

Cogent's Bezuclastinib NDA Accepted For Advanced Systemic Mastocytosis; PDUFA Set For June 2027

Cogent Biosciences (COGT) announced FDA acceptance of its NDA for Bezuclastinib to treat Advanced Systemic Mastocytosis, with a PDUFA target date of June 2027. The NDA is supported by APEX trial data showing a 65% overall response rate and 79% 12-month progression-free survival. The FDA has not identified any review issues. COGT is also advancing NDAs for other indications. The stock is currently trading at $33.49, up 0.24%.

Original reporting
Published Sep 15, 2026, 2:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 3:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$COGT
Bullish
high confidence
Mentioned
$COGT
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$COGTBullishHigh
01

Why it matters

The NDA acceptance signals a near-term catalyst that could drive significant stock movement.

02

Market read

Regulatory milestone for a rare disease therapy; high relevance for biotech traders.

03

What to watch

Potential competition from other mastocytosis therapies and reimbursement uncertainties.

Relevance 8/10Novelty 8/10Timing: today

Background

Cogent Biosciences is a clinical-stage biotech focusing on KIT-driven diseases.

Company-level read

Ticker impact

$COGTBullishHigh confidence
Context

FDA accepted Cogent Biosciences' NDA for Bezuclastinib, providing trial data and a PDUFA date.

Expected impact

Short-term upside as investors price in potential approval.

Evidence & confidence

First report of NDA acceptance and strong trial results; biotech stocks react strongly to FDA milestones.

Market effects

May lift other KIT inhibitor developers and rare disease biotech sector.

Positive for US biotech market.

Limited to biotech investors worldwide.

Counterpoint

Approval is not guaranteed; FDA may request additional data, risking a pullback.

Key entities

  • Cogent Biosciences Inc.

    Biotech developing Bezuclastinib for advanced systemic mastocytosis.

  • FDA

    U.S. Food and Drug Administration reviewing the NDA.

Related articles

$COGTMed

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Cogent Biosciences, Inc. (COGT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Applicatio

$INTCMed

Intel semiconductors granted one-year waiver to robotics ban

The FCC granted Intel a one-year waiver to use foreign-made robotics in its U.S. semiconductor production. The waiver allows Intel to continue operating its Automated Guided Vehicles (AGVs), which are critical to its chip manufacturing. Intel cited a lack of domestic alternatives and the potential disruption to its supply chain if it had to replace the AGVs. The FCC's quick approval and Intel's importance to U.S. chip manufacturing plans are noted.

$CMed

Citi Receives Approval from the China Securities Regulatory Commission to Establish A Wholly-Owned Securities Company in China, Citigroup Securities Company Limited

Citi received approval from China's CSRC to establish a wholly-owned securities firm, Citigroup Securities (China) Company Limited (CSCCL). The license allows CSCCL to offer equities brokerage, underwriting, research, and trading services. Citi will complete regulatory procedures for operations to begin. CSCCL, based in Shanghai, will serve domestic and foreign clients with onshore capital markets services.

$BAHigh

Nearly 2,000 Boeing 737s Must Get Tail Inspections After Jets Pitched Up And Down Mid-Flight

The FAA issued a directive requiring inspections of 1,987 US-registered Boeing 737NG aircraft due to potential control issues from excessive horizontal stabilizer movement. The order, effective November 23, follows reports of pitch oscillations. Airlines like United and Alaska requested delays or adjustments, but the FAA rejected them. Inspections are estimated to cost over $1 million for the US fleet. Southwest Airlines operates the largest 737NG fleet worldwide.

$METAMed

Sandberg said 'I don't know' to 6 Facebook app-vetting gaps, video shows

Sheryl Sandberg, former Facebook COO, testified in a 2026 New Mexico trial that she was unaware of certain app developer vetting practices between 2012 and 2018. The jury found 26 of 29 Facebook statements misleading, leading to a $25 billion penalty. Sandberg defended Facebook's data practices, stating it does not sell user data. The case involves 43.9 million alleged violations under New Mexico's Unfair Practices Act.